LATS1 and neoplasm: Mechanically, LATS1/2-deficient tumor cells secreted robust level of nucleic-acid-rich extracellular vesicles, which activated IFN-I response via TLR-MYD88/TRIF signaling and enhanced antitumor immune responses (122).